GEOVAX LABS INC

NASDAQ: GOVX (GeoVax Labs, Inc.)

最近更新时间: 25 Nov, 6:48PM

0.379

0.00 (-0.16%)

前收盘价格 0.380
收盘价格 0.385
成交量 340,340
平均成交量 (3个月) 794,207
市值 11,270,214
价格/销量 (P/S) 1.85
股市价格/股市净资产 (P/B) 2.42
52周波幅
0.373 (-1%) — 3.01 (693%)
利润日期 13 Nov 2025
营业利益率 (TTM) -330.18%
稀释每股收益 (EPS TTM) -2.80
流动比率 (MRQ) 2.55
营业现金流 (OCF TTM) -24.68 M
杠杆自由现金流 (LFCF TTM) -16.53 M
资产报酬率 (ROA TTM) -915.19%
股东权益报酬率 (ROE TTM) -78,814.56%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 GeoVax Labs, Inc. 看跌 看跌

AIStockmoo 评分

1.1
分析师共识 1.5
内部交易活动 NA
价格波动 0.5
技术平均移动指标 5.0
技术振荡指标 -2.5
平均 1.13

相关股票

股票 市值 DY P/E(TTM) P/B
GOVX 11 M - - 2.42
MRNA 12 B - - 1.23
JAZZ 10 B - - 2.53
COGT 6 B - - 30.40
SANA 1 B - - 6.74
ABCL 1 B - - 1.12

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

部门 Healthcare
行业 Biotechnology
投资方式 Small Value
内部持股比例 0.42%
机构持股比例 7.72%
52周波幅
0.373 (-1%) — 3.01 (693%)
6.00 (1,481.44%)
总计 1 购买
公司 日期 目标价格 调整类型 价格@调整类型
D. Boral Capital 19 Nov 2025 6.00 (1,481.44%) 购买 0.415
26 Sep 2025 9.00 (2,272.17%) 购买 0.646

该时间范围内无数据。

日期 类型 细节
11 Dec 2025 公告 GeoVax Addresses Identification of New Mpox Variant
10 Dec 2025 公告 GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
09 Dec 2025 公告 GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
08 Dec 2025 公告 GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
24 Nov 2025 公告 GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
13 Nov 2025 公告 GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
10 Nov 2025 公告 GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
10 Nov 2025 公告 GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
04 Nov 2025 公告 GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
03 Nov 2025 公告 GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
30 Oct 2025 公告 BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
29 Oct 2025 公告 GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
28 Oct 2025 公告 GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
20 Oct 2025 公告 GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
16 Oct 2025 公告 GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
13 Oct 2025 公告 GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
09 Oct 2025 公告 GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
07 Oct 2025 公告 GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
01 Oct 2025 公告 GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
30 Sep 2025 公告 GeoVax Labs Announces $2.5 Million Registered Direct Offering
29 Sep 2025 公告 GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
24 Sep 2025 公告 GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
22 Sep 2025 公告 GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
18 Sep 2025 公告 GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
15 Sep 2025 公告 GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票